# IRRA flow Portfolio

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/irra-flow-portfolio
Canonical HTML page: https://getbiobrief.com/entity/irra-flow-portfolio

## Timeline

- **2027**: Commercial Drug Delivery Readiness Target — ClearPoint aims to have its commercial infrastructure and installed base ready to support partner drug launches.
- **2026-08-03**: Q2 2026 Earnings Release — ClearPoint Neuro announces quarterly results and highlights FDA guidance reversal and commercial restructuring.
- **2026-07**: CAL Facility Possession — ClearPoint takes possession of the ClearPoint Advanced Laboratories, enabling new in-house services revenue from Q3 onward.
- **2026-06-30**: Second Quarter 2026 Ends — ClearPoint Neuro's fiscal Q2 concludes with $10.9M in revenue, 18% overall growth, but a 15% decline in Biologics and Drug Delivery.
- **2026**: Potential Partner BLA Submissions — Following FDA's rare disease guidance reversal, biopharma partners may file Biologics License Applications later this year.

## Recent coverage (1 stories)

### ClearPoint Neuro Biologics Revenue Drops 15% in Q2, But New Lab Services Promise Turnaround
2026-08-04 02:31:59 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

ClearPoint Neuro's Q2 biologics revenue fell 15% as clinical trial product shipments slowed, but the newly operational CAL facility and an FDA regulatory pivot on rare diseases are expected to re-ignite growth in the cell and gene therapy delivery segment.
Full story: https://getbiobrief.com/story/clearpoint-neuro-biologics-decline-cal-lab-services-turnaround

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.